{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:53:25Z","timestamp":1786982005512,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11523-026-01205-4","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T05:24:14Z","timestamp":1774502654000},"page":"373-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-6658","authenticated-orcid":false,"given":"Natalia A. Quijano","family":"Card\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"P\u00e9rez-Ruixo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Zuppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh N.","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahor","family":"Haddish-Berhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"Van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"1205_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:1\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1205_CR2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","volume":"13","author":"AS Bruno","year":"2020","unstructured":"Bruno AS, Willson JL, Opalinska JM, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma. Expert Rev Hematol. 2020;13:1017\u201325.","journal-title":"Expert Rev Hematol"},{"key":"1205_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101:396\u2013406.","journal-title":"Haematologica"},{"key":"1205_CR4","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"1205_CR5","unstructured":"TECVAYLI\u00ae (teclistamab-cqyv) injection, for subcutaneous use [package insert]. Janssen Biotech, Inc.; 2024."},{"key":"1205_CR6","unstructured":"Perrot A, Uttervall K, Kort\u00fcm M, et al. Safety results from REALiTEC: a multi-country observational retrospective study of teclistamab in relapsed\/refractory multiple myeloma outside of clinical trial. Presented at: 11th Controversies in Multiple Myeloma (COMy) World Congress; May 15\u201318, 2025; Paris, France."},{"key":"1205_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, van de Donk NWCJ, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:7540.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1205_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.6004\/jadpro.2025.16.2.15","volume":"16","author":"Z Mahmoudjafari","year":"2025","unstructured":"Mahmoudjafari Z, O\u2019Brien J. Successful management of patients receiving bispecific antibodies for hematologic malignancies. J Adv Pract Oncol. 2025;16(2):31\u20135.","journal-title":"J Adv Pract Oncol"},{"key":"1205_CR9","unstructured":"TECVAYLI\u00ae (teclistamab-cqyv) injection [package insert]. Janssen Biotech, Inc.; 2022."},{"key":"1205_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","volume":"18","author":"X Miao","year":"2023","unstructured":"Miao X, Wu LS, Lin SXW, et al. Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1. Target Oncol. 2023;18:667\u201384.","journal-title":"Target Oncol"},{"key":"1205_CR11","unstructured":"Niu J, Guo Y, Peng T, et al. Development of a quantitative systems pharmacology model to support the clinical development of T cell redirecting bispecific antibodies for patients with relapse\/refractory multiple myeloma. Presented at: 14th American Conference on Pharmacometrics (ACoP14); November 5\u20138, 2023; National Harbor, MD, USA."},{"key":"1205_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11523-025-01149-1","volume":"20","author":"Y Guo","year":"2025","unstructured":"Guo Y, Niu J, Carde NAQ, et al. Teclistamab dosing in responders: modeling and simulation results from the MajesTEC-1 study in relapsed\/refractory multiple myeloma. Target Oncol. 2025;20:651\u201361.","journal-title":"Target Oncol"},{"key":"1205_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"1205_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665\u201374.","journal-title":"Lancet"},{"key":"1205_CR15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/psp4.12928","volume":"12","author":"J Weddell","year":"2023","unstructured":"Weddell J. Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. CPT Pharmacomet Syst Pharmacol. 2023;12:1726\u201337.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1205_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-020-00145-7","volume":"6","author":"I Hosseini","year":"2020","unstructured":"Hosseini I, Gadkar K, Stefanich E, et al. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020;6:28.","journal-title":"NPJ Syst Biol Appl"},{"key":"1205_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105260","volume":"146","author":"X Jiang","year":"2020","unstructured":"Jiang X, Chen X, Jaiprasart P, et al. Development of a minimal physiologically-based pharmacokinetic\/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans. Eur J Pharm Sci. 2020;146:105260.","journal-title":"Eur J Pharm Sci"},{"key":"1205_CR18","unstructured":"RoAcetemra (tocilizumab). [Summary of product characteristics]. Grenzach-Wyhlen, Germany, Roche Registration GmbH; 2025."},{"key":"1205_CR19","unstructured":"TYENNE\u00ae (tocilizumab-aazg). [Summary of product characteristics]. Fresenius Kabi Deutschland GmbH; 2025."},{"key":"1205_CR20","unstructured":"AVTOZMA\u00ae (tocilizumab-anoh) injection [highlights of prescribing information]. CELLTRION, Inc.; 2025."},{"key":"1205_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1205_CR22","unstructured":"R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011."},{"key":"1205_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ITT.S202015","volume":"8","author":"H Murthy","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC, et al. Cytokine release syndrome: current perspectives. Immunotargets Ther. 2019;8:43\u201352.","journal-title":"Immunotargets Ther."},{"key":"1205_CR24","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-846","volume":"83","author":"N Afzal","year":"2023","unstructured":"Afzal N, Li T, Chiu C, et al. Abstract 846: Utilizing quantitative systems pharmacology (QSP) model to understand cytokine release syndrome (CRS) following administration of epcoritamab in DLBCL patients. Cancer Res. 2023;83:846.","journal-title":"Cancer Res"},{"key":"1205_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/cpt.3588","volume":"117","author":"T Li","year":"2025","unstructured":"Li T, Gibiansky L, Parikh A, et al. Optimal dosing regimen for epcoritamab, a subcutaneous bispecific antibody, in relapsed or refractory large B-cell lymphoma. Clin Pharmacol Ther. 2025;117:1437\u201350.","journal-title":"Clin Pharmacol Ther"},{"key":"1205_CR26","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1182\/blood-2022-169971","volume":"140","author":"M Elmeliegy","year":"2022","unstructured":"Elmeliegy M, Viqueira A, Vandendries E, et al. Dose optimization to mitigate the risk of CRS with elranatamab in multiple myeloma. Blood. 2022;140:7174\u20135.","journal-title":"Blood"},{"key":"1205_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpt.3361","volume":"116","author":"M Elmeliegy","year":"2024","unstructured":"Elmeliegy M, Chen J, Dontabhaktuni A, et al. Dosing strategies and quantitative clinical pharmacology for bispecific T-cell engagers development in oncology. Clin Pharmacol Ther. 2024;116:637\u201346.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01205-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:54:58Z","timestamp":1780131298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01205-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01205-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MajesTEC-1 was funded by Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N.W.C.J.V.d.D. has received research support from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, Cellectis, and Bristol Myers Squibb, all paid to institution; and serves on advisory boards for Janssen Pharmaceuticals, Amgen, Celgene, Bristol Myers Squibb, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Galapagos, Kite Pharma, Merck, Pfizer, AbbVie, and Servier. A.L.G. served in a consulting or advisory role for AbbVie, Amgen, Bristol Myers Squibb\/Celgene, CDR-Life, Gracell, GSK, Janssen Oncology, Novartis, Regeneron, and Smart Immune; received travel, accommodations, or expenses from Janssen; has a patent in the field of CAR-T cell therapy; and received research funding from CRISPR Therapeutics, Janssen Oncology, Novartis, and Tmunity Therapeutics. J.V.M. was a consultant for Johnson & Johnson in 2024. N.A.Q.C., J.N., Y.G., J.Z., X.Q., Y.S., C.P.R., D.V., C.H., T.S., A.Z., K.C., R.K., M.N.S., W.W., and N.H.B. are current employees of Johnson & Johnson and may hold stock in Johnson & Johnson.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation. The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent prior to treatment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data sharing policy of Johnson & Johnson is available at\n                      \n                      . As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"N.A.Q.C., J.N., Y.G., J.Z., X.Q., Y.S., C.P.R., D.V., C.H., T.S., A.Z., K.C., R.K., M.N.S., W.W., and N.H.B. contributed to the development of the analysis plan, data analysis, and interpretation. J.N., J.Z., X.Q., Y.S., C.P.R., M.N.S., and W.W. contributed to the population pharmacokinetic and\/or quantitative systems pharmacology model development. C.H., T.S., A.Z., K.C., and R.K. contributed to the clinical study design, managed the clinical study, and provided clinical oversight. N.W.C.J.V.d.D., A.L.G., and J.V.M. cared for patients, supported the clinical trial, and contributed to data collection. All authors contributed to writing, critically reviewing, and revising the manuscript. All authors approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}